CML WHO 5th edition UPDATE- key points
Acclerated phase is no longer required .
Resistance to TKI ( tyrosine kinase is important prognostic factor than Acclerated phase)
criteria for blast phase in CML
>/= 20 % Myeloid Blast in blood or bone marrow.
Presence of extramedullary prolioferation of blast
Presence of increased Lymphoblast in peripheral blood or bone marrow optial cytoff forlymphoblast is yet to be established , require more studies
The significance of low-level B-lymphoblasts remain unclear and require additional studies.
Definition of CML
chronic myeloid leukemia (CML), is a type of myeloproliferative neoplasm (MPN) defined by the abnormal proliferation of granulocytes. This abnormal growth originates from a single, mutated stem cell harboring a t(9;22)(q34.1;q11.2) chromosomal translocation. This translocation results in the formation of the Philadelphia (Ph) chromosome, which contains the BCR-ABL1 fusion gene
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22. PMID: 35732831; PMCID: PMC9252913.